May 18, 2026 – Baxfendy (baxdrostat) from AstraZeneca has received FDA approval as the world's first aldosterone synthase inhibitor (ASI) for use in combination with other antihypertensive drugs in adult patients with hypertension whose blood pressure is not adequately controlled on existing therapy.
Key Clinical Trial Data
This approval is based on positive results from the Phase 3 BaxHTN trial. Data showed that Baxfendy provided a statistically significant and clinically meaningful reduction in systolic blood pressure (SBP) in patients with uncontrolled or resistant hypertension:
Baxfendy 2 mg group: mean SBP reduction from baseline of 15.7 mmHg (placebo‑adjusted reduction of 9.8 mmHg);
Baxfendy 1 mg group: mean SBP reduction from baseline of 14.5 mmHg (placebo‑adjusted reduction of 8.7 mmHg).
Innovative Mechanism of Action
Baxfendy is a first‑in‑class, highly selective, potent aldosterone synthase inhibitor that lowers blood pressure by specifically inhibiting the production of aldosterone⁸. Aldosterone is a hormone that raises blood pressure to unhealthy levels and increases the risk of heart and kidney problems.
Indication and Dosage
Indication
Baxfendy is an aldosterone synthase inhibitor indicated in combination with other antihypertensive drugs for the treatment of hypertension in adult patients whose blood pressure is not adequately controlled on other antihypertensive therapies. Lowering blood pressure reduces the risk of fatal and non‑fatal cardiovascular events, primarily stroke and myocardial infarction.
Recommended Dosage
Usual dosage: 2 mg orally once daily.
Patients at increased risk for hyperkalemia or hyponatremia: 1 mg orally once daily.
Warnings and Precautions
1. Hyperkalemia
Baxfendy can cause hyperkalemia. Assess serum potassium before initiating treatment and monitor periodically during treatment.
More frequent monitoring is required in high‑risk patients (e.g., age ≥65 years, diabetes, chronic kidney disease, or concomitant use of drugs that increase serum potassium).
If hyperkalemia occurs, treat it and consider interrupting or discontinuing Baxfendy. Permanently discontinue in patients with recurrent clinically significant hyperkalemia.
2. Hyponatremia
Baxfendy can cause hyponatremia. Monitor serum sodium before initiating treatment and periodically during treatment.
More frequent monitoring is required in patients with low baseline serum sodium or at increased risk. If clinically significant hyponatremia occurs, treat it and consider interrupting or discontinuing Baxfendy. Permanently discontinue in patients with recurrent hyponatremia.
Adverse Reactions
In pooled placebo‑controlled trials, the most common adverse reactions (incidence ≥2% and at least 1% higher than placebo) in the Baxfendy 1 mg and 2 mg groups, respectively, were:
Hyperkalemia (6.6%, 10.2%);
Hypotension (2.1%, 3.6%);
Hyponatremia (2.1%, 3.2%);
Dizziness (3.0%, 2.9%);
Muscle spasms (1.8%, 2.9%).
Drug Interactions
Drugs that increase serum potassium: more frequent monitoring of serum potassium is required when used concomitantly, as the risk of hyperkalemia may be increased.
Strong or moderate CYP3A inducers: more frequent monitoring of Baxfendy efficacy is required when used concomitantly (Baxfendy is a CYP3A substrate).
